Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Kraus

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Current Medical Research and Opinion|April 5, 2007
Onset of efficacy of tolterodine extended release in patients with overactive bladderDavid O Sussman, Stephen R Kraus, Martin Carlsson, et al.
Drugs & Aging|September 3, 2010
Vulnerable elderly patients and overactive bladder syndromeStephen R Kraus, Tamara Bavendam, Tiffany Brake, et al.
Neurourology and Urodynamics|August 22, 2012
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trialsCatherine E DuBeau, Jon D Morrow, Stephen R Kraus, et al.
Neurourology and Urodynamics|August 23, 2020
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United StatesStephen R Kraus, Aki Shiozawa, Shelagh M Szabo, et al.
Urology|April 21, 2007
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American menAlayne D Markland, Ian M Thompson, Donna P Ankerst, et al.
Drugs & Aging|January 27, 2012
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studiesPeter K Sand, John Heesakkers, Stephen R Kraus, et al.
Urology|October 27, 2010
Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladderStephen R Kraus, José Luis Ruiz-Cerdá, Diane Martire, et al.
Urology|March 18, 2003
Long-term results for Malone antegrade continence enema for adults with neurogenic bowel diseaseJoel M H Teichman, Nasim Zabihi, Stephen R Kraus, et al.
Neurourology and Urodynamics|February 13, 2010
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstructionStephen R Kraus, Roger Dmochowski, Michael E Albo, et al.
Urology|September 27, 2008
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OABClaus G Roehrborn, Steven A Kaplan, Stephen R Kraus, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Current Medical Research and Opinion|April 5, 2007
Onset of efficacy of tolterodine extended release in patients with overactive bladderDavid O Sussman, Stephen R Kraus, Martin Carlsson, et al.
Drugs & Aging|September 3, 2010
Vulnerable elderly patients and overactive bladder syndromeStephen R Kraus, Tamara Bavendam, Tiffany Brake, et al.
Neurourology and Urodynamics|August 22, 2012
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trialsCatherine E DuBeau, Jon D Morrow, Stephen R Kraus, et al.
Neurourology and Urodynamics|August 23, 2020
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United StatesStephen R Kraus, Aki Shiozawa, Shelagh M Szabo, et al.
Urology|April 21, 2007
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American menAlayne D Markland, Ian M Thompson, Donna P Ankerst, et al.
Drugs & Aging|January 27, 2012
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studiesPeter K Sand, John Heesakkers, Stephen R Kraus, et al.
Urology|October 27, 2010
Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladderStephen R Kraus, José Luis Ruiz-Cerdá, Diane Martire, et al.
Urology|March 18, 2003
Long-term results for Malone antegrade continence enema for adults with neurogenic bowel diseaseJoel M H Teichman, Nasim Zabihi, Stephen R Kraus, et al.
Neurourology and Urodynamics|February 13, 2010
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstructionStephen R Kraus, Roger Dmochowski, Michael E Albo, et al.
Urology|September 27, 2008
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OABClaus G Roehrborn, Steven A Kaplan, Stephen R Kraus, et al.
Pageof 6